Pfizer invests $500 million in expanding gene therapy facility
Carl O Donnell
Pfizer Inc is investing $500 million to expand a manufacturing facility in Sanford, North Carolina, that plays a central role in its efforts to become a major player in gene therapy, the company said on Wednesday.
The investment will add additional capacity and capabilities to a facility that makes some of Pfizers most closely watched experimental treatments.
The Sanford plant manufactures therapies used for the companys late-stage experimental treatments for Duchenne Muscular Dystrophy (DMD) and hemophilia B therapies, among other gene therapies